Related Experiment Video
Updated: Apr 21, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Optimization of a nonviral transfection system to evaluate Cox-2 controlled interleukin-4 expression for
Annemarie Lang1, Johannes Neuhaus, Moritz Pfeiffenberger
1Institute of Immunology, Department of Veterinary Medicine, Freie Universität Berlin, Germany; Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany; German Rheumatism Research Center, Berlin, Germany; Berlin-Brandenburg School of Regenerative Therapies, Charité University Hospital, Berlin, Germany.
Background:
Gene therapy appears to have the potential for achieving a long-term remedy for osteoarthritis (OA). However, there is a risk of adverse reactions, especially when using cytomegalovirus-controlled expression. To provide a safe application, we focused on the expression of therapeutic cytokines [e.g. interleukin (IL)-4] in a disease-responsive manner by use of the previously cloned Cox-2 promoter as 'genetic switch'. In the present study, we report the functionality of a controlled gene therapeutic system in an equine osteoarthritic cell model.
Methods:
Different nonviral transfection reagents were tested for their efficiency on equine chondrocytes stimulated with equine IL-1β or lipopolysaccharide to create an inflammatory environment. To optimize the transfection, we successfully redesigned the vector by excluding the internal ribosomal entry site (IRES). The functionality of our Cox-2 promoter construct with respect to expressing IL-4 was proven at the mRNA and protein levels and the anti-inflammatory potential of IL-4 was confirmed by analyzing the expression of IL-1β, IL-6, IL-8, matrix metalloproteinase (MMP)-1, MMP-3 and tumor necrosis factor (TNF)-α using a quantitative polymerase chain reaction.
Results:
Nonviral transfection reagents yielded transfection rates from 21% to 44% with control vectors with and without IRES, respectively. Stimulation of equine chondrocytes resulted in a 20-fold increase of mRNA expression of IL-1β. Such exogenous stimulation of chondrocytes transfected with pNCox2-IL4 led to an increase of IL-4 mRNA expression, whereas expression of inflammatory mediators decreased. The timely link between these events confirms the anti-inflammatory potential of synthesized IL-4.
Conclusions:
We consider that this approach has significant potential for translation into a useful anti-inflammation therapy. Molecular tools such as the described therapeutic plasmid pave the way for a local-controlled, self-limiting gene therapy.
Insights
This study developed a safe gene therapy for osteoarthritis using a Cox-2 promoter to control interleukin-4 (IL-4) expression in equine cells. The system successfully reduced inflammation, showing potential for a novel anti-inflammatory treatment.
Area of Science:
- Biotechnology
- Molecular Biology
- Veterinary Medicine
Background:
- Osteoarthritis (OA) gene therapy offers long-term relief but faces safety concerns with cytomegalovirus (CMV)-controlled expression.
- A novel approach utilizes a disease-responsive Cox-2 promoter as a 'genetic switch' for controlled therapeutic cytokine expression, such as interleukin (IL)-4.
- This study investigates a controlled gene therapeutic system in an equine osteoarthritis cell model.
Purpose of the Study:
- To evaluate the functionality of a Cox-2 promoter-driven gene therapeutic system for expressing interleukin-4 (IL-4) in an equine osteoarthritis model.
- To assess the anti-inflammatory potential of IL-4 delivered via this controlled gene therapy system.
- To optimize nonviral transfection methods for equine chondrocytes.
Main Methods:
- Nonviral transfection reagents were tested on equine chondrocytes stimulated with IL-1β or lipopolysaccharide.
- A vector was redesigned by excluding the internal ribosomal entry site (IRES) to optimize transfection.
- The functionality of the Cox-2 promoter construct for IL-4 expression was confirmed at mRNA and protein levels, and its anti-inflammatory effects were analyzed via quantitative PCR.
Main Results:
- Nonviral transfection achieved rates of 21% to 44%.
- Stimulation of equine chondrocytes led to a 20-fold increase in IL-1β mRNA expression.
- Chondrocytes transfected with pNCox2-IL4 showed increased IL-4 mRNA expression upon stimulation, while inflammatory mediators decreased, confirming IL-4's anti-inflammatory potential.
Conclusions:
- The developed approach shows significant potential for translation into an effective anti-inflammation therapy for osteoarthritis.
- This molecular tool enables local-controlled, self-limiting gene therapy, addressing safety concerns associated with traditional methods.
- The Cox-2 promoter serves as a viable 'genetic switch' for responsive and safe gene delivery.
